Free Trial
NASDAQ:NRIX

Nurix Therapeutics (NRIX) Stock Price, News & Analysis

$15.17
0.00 (0.00%)
(As of 05/24/2024 ET)
Today's Range
$14.87
$15.66
50-Day Range
$12.02
$17.48
52-Week Range
$4.22
$18.12
Volume
530,542 shs
Average Volume
1.01 million shs
Market Capitalization
$745.61 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$21.88

Nurix Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.88 Rating Score
Upside/​Downside
44.2% Upside
$21.88 Price Target
Short Interest
Bearish
14.04% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.70mentions of Nurix Therapeutics in the last 14 days
Based on 6 Articles This Week
Insider Trading
Selling Shares
$85,756 Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($3.09) to ($3.26) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.03 out of 5 stars

Medical Sector

589th out of 923 stocks

Pharmaceutical Preparations Industry

259th out of 412 stocks

NRIX stock logo

About Nurix Therapeutics Stock (NASDAQ:NRIX)

Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications. It is also developing NX-0479/GS-6791, a IRAK4 degrader for the treatment of rheumatoid arthritis and other inflammatory diseases. The company has a strategic collaboration agreement with Gilead Sciences, Inc., Sanofi S.A., and Seagen Inc. co-development and co-commercialization for multiple drug candidates. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. Nurix Therapeutics, Inc. was incorporated in 2009 and is headquartered in San Francisco, California.

NRIX Stock Price History

NRIX Stock News Headlines

Nurix Therapeutics Announces Board Chair Transition
Nurix Therapeutics, Inc. (NRIX)
Key Takeaways From Nurix Therapeutics Analyst Ratings
Nurix Therapeutics Announces Proposed Public Offering
See More Headlines
Receive NRIX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Nurix Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
4/10/2024
Today
5/26/2024
Next Earnings (Estimated)
7/11/2024
Fiscal Year End
11/30/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:NRIX
Fax
N/A
Employees
284
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$21.88
High Stock Price Target
$31.00
Low Stock Price Target
$10.00
Potential Upside/Downside
+44.2%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.88
Research Coverage
8 Analysts

Profitability

Net Income
$-143,950,000.00
Net Margins
-178.93%
Pretax Margin
-178.82%

Debt

Sales & Book Value

Annual Sales
$76.99 million
Book Value
$4.13 per share

Miscellaneous

Free Float
45,612,000
Market Cap
$745.61 million
Optionable
Optionable
Beta
2.10
10 Best Stocks to Own in 2024 Cover

Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio.

Get This Free Report

Key Executives

  • Dr. Arthur T. Sands M.D. (Age 62)
    Ph.D., CEO, President & Director
    Comp: $986.32k
  • Mr. Johannes Van Houte (Age 58)
    Chief Financial Officer
    Comp: $681.98k
  • Dr. Gwenn M. Hansen Ph.D. (Age 53)
    Chief Scientific Officer
    Comp: $702.75k
  • Dr. John Kuriyan Ph.D.
    Founder & Member of Scientific Advisory Board
  • Mr. Michael Rapé Ph.D.
    Founder & Member of Scientific Advisory Board
  • Dr. Arthur Weiss M.D.
    Ph.D., Founder & Member of Scientific Advisory Board
  • Rita Kwong
    Senior Accounting Manager
  • Dr. Christine Ring J.D. (Age 59)
    Ph.D., Chief Legal Officer, Secretary & Chief Compliance Officer
    Comp: $595.83k
  • Mr. Eric C. Schlezinger J.D. (Age 57)
    Chief People Officer
  • Dr. Jason Kantor Ph.D.
    Chief Business Officer

NRIX Stock Analysis - Frequently Asked Questions

Should I buy or sell Nurix Therapeutics stock right now?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Nurix Therapeutics in the last twelve months. There are currently 1 hold rating and 7 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" NRIX shares.
View NRIX analyst ratings
or view top-rated stocks.

What is Nurix Therapeutics' stock price target for 2024?

8 analysts have issued 1-year target prices for Nurix Therapeutics' stock. Their NRIX share price targets range from $10.00 to $31.00. On average, they predict the company's stock price to reach $21.88 in the next twelve months. This suggests a possible upside of 44.2% from the stock's current price.
View analysts price targets for NRIX
or view top-rated stocks among Wall Street analysts.

How have NRIX shares performed in 2024?

Nurix Therapeutics' stock was trading at $10.32 on January 1st, 2024. Since then, NRIX stock has increased by 47.0% and is now trading at $15.17.
View the best growth stocks for 2024 here
.

When is Nurix Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, July 11th 2024.
View our NRIX earnings forecast
.

How were Nurix Therapeutics' earnings last quarter?

Nurix Therapeutics, Inc. (NASDAQ:NRIX) posted its earnings results on Wednesday, April, 10th. The company reported ($0.76) EPS for the quarter, topping the consensus estimate of ($0.80) by $0.04. The business had revenue of $16.59 million for the quarter, compared to analysts' expectations of $14.58 million. Nurix Therapeutics had a negative trailing twelve-month return on equity of 67.08% and a negative net margin of 178.93%.

What ETFs hold Nurix Therapeutics' stock?
What other stocks do shareholders of Nurix Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Nurix Therapeutics investors own include Datadog (DDOG), Intel (INTC), AbbVie (ABBV), Alibaba Group (BABA), BigCommerce (BIGC), Beyond Meat (BYND), Delta Air Lines (DAL), DocuSign (DOCU), Fastly (FSLY) and Fiverr International (FVRR).

When did Nurix Therapeutics IPO?

Nurix Therapeutics (NRIX) raised $150 million in an initial public offering on Friday, July 24th 2020. The company issued 8,800,000 shares at a price of $16.00-$18.00 per share. J.P. Morgan, Piper Sandler and Stifel acted as the underwriters for the IPO and Needham & Company was co-manager.

Who are Nurix Therapeutics' major shareholders?

Nurix Therapeutics' stock is owned by many different institutional and retail investors. Top institutional shareholders include Redmile Group LLC (9.12%), Vanguard Group Inc. (5.26%), Price T Rowe Associates Inc. MD (4.47%), Wasatch Advisors LP (2.52%), Bain Capital Life Sciences Investors LLC (2.30%) and Affinity Asset Advisors LLC (1.65%). Insiders that own company stock include Christine Ring, Gwenn Hansen, Houte Hans Van, Pierre Beaurang and Stefani Wolff.
View institutional ownership trends
.

How do I buy shares of Nurix Therapeutics?

Shares of NRIX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:NRIX) was last updated on 5/26/2024 by MarketBeat.com Staff

From Our Partners